FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

hington, D.C.	. 20549		

1	OMB APPE	ROVAL
	OMB Number:	3235-0287
1	Estimated average bu	ırden

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>LERNER RICHARD A</u>					2. Issuer Name and Ticker or Trading Symbol Intra-Cellular Therapies, Inc. [ ITCI ]								5. Relationship of (Check all applications)  X Directors		cable) or	g Pers	10% Ov	vner	
(Last)	`	irst) JLAR THERAP	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 05/27/2020								Officer below)	(give title		Other (s below)	specify	
430 EAST 29TH STREET				4. 11	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable						
(Street) NEW YORK NY 10016											ine) X	•							
(City)	(S	tate)	(Zip)																
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)					Execution Date,		Code (	Transaction Disposed Of (D) Code (Instr. 5)			Acquired (A) or (D) (Instr. 3, 4 and		5. Amount of Securities Beneficially Owned Following Reported		Form: Direct (D) or Indirect		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code V Amount (A) or (D)				Price	е	Transact (Instr. 3 a	ction(s)			(111311. 4)				
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	titve Conversion Date Execution Date, ity or Exercise (Month/Day/Year) if any		ate, T		ransaction of ode (Instr. Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		D	. Price of erivative ecurity nstr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)			
					Code	v	(A)	(D)	Date Exercisab		Expiration Date	Title	Amour or Number of Shares	er					
Stock Option (right to buy)	\$22.02	05/27/2020			A		20,000		05/27/202	!1 (	05/26/2030	Common Stock	20,00	00	\$0.00	20,000	)	D	

**Explanation of Responses:** 

Remarks:

/s/ Lawrence J. Hineline, Attorney-in-fact

\*\* Signature of Reporting Person Date

05/28/2020

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

 $<sup>^{\</sup>star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

<sup>\*\*</sup> Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).